Business
Biovica Secures Three New Work Orders in Pharma Services of 2,5 MSEK in Value
UPPSALA, SE / ACCESS Newswire / June 10, 2025 /Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has signed three new work orders within its Pharma Services business, with a combined ...
About this update from Biovica International Ab Class B
[{"type":"text","content":"UPPSALA, SE / ACCESS Newswire / June 10, 2025 / ","length":47,"tagName":"p"},{"type":"text","content":"Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, a leader in blood-based cancer monitoring, has signed three new work orders within its Pharma Services business, with a combined value of approximately SEK 2.5 million. The agreements are for TKa testing services with existing customers.","length":308,"tagName":"p"},{"type":"text","content":"Two of the three work orders were placed by the Tier-1 (revenues >10 BUSD) U.S. pharmaceutical company which recently entered into a broader service agreement with Biovica, including a record-breaking SEK 4 million work order. These latest orders will support the development of next-generation CDK4/6 inhibitors. The orders are a combination of retrospective analysis, that will be performed in the coming months, and prospective analysis that will be performed over ~2 years.","length":480,"tagName":"p"},{"type":"text","content":""I'm pleased to see that our Pharma customers recognize the value of DiviTum® TKa and are returning for continued use. The reliable and meaningful data it provides continues to drive demand from leading pharmaceutical companies, who use it in the development of new cancer therapies that will benefit patients.," said Anders Rylander, CEO of Biovica.","length":364,"tagName":"p"},{"type":"text","content":"Contact","length":7,"tagName":"p"},{"type":"text","content":"Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: [email protected]","length":80,"tagName":"p"},{"type":"text","content":"Anders Morén, CFOPhone: +46 73 125 92 46E-mail: [email protected]","length":74,"tagName":"p"},{"type":"text","content":"Biovica - Treatment decisions with greater confidence","length":53,"tagName":"p"},{"type":"text","content":"Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patient...